Jazz Pharmaceuticals Business Summary

Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company that generates revenue primarily through the commercialization and sale of proprietary therapeutics, with a business model centered on high-margin specialty medicines for unmet needs. The company operates through two primary segments: Neuroscience and Oncology. The Neuroscience portfolio, which accounts for approximately 74% of total revenue, is anchored by the low-sodium oxybate therapy Xywav and the cannabinoid-based epilepsy treatment Epidiolex, acquired via the $7.2 billion purchase of GW Pharmaceuticals. The Oncology segment is a high-growth vertical featuring Zepzelca for small cell lung cancer and Rylaze for acute lymphoblastic leukemia. Jazz competes directly with firms such as Harmony Biosciences, Axsome Therapeutics, Supernus Pharmaceuticals, and Corcept Therapeutics; it maintains a dominant market position in the sleep medicine and rare epilepsy sectors while aggressively pivoting toward a diversified oncology pipeline to mitigate legacy patent cliffs. The company was co-founded in 2003 by Bruce C. Cozadd, who currently serves as Chairperson of the Board after retiring as CEO in August 2025. Leadership is now spearheaded by President and CEO Renée Galá, an industry veteran with over 30 years of experience who previously served as the company’s CFO and COO following roles at GRAIL and Theravance Biopharma. The executive team includes Philip L. Johnson as EVP and Chief Financial Officer (formerly of Eli Lilly), Thomas Riga as Chief Business Officer (appointed January 2026 following the Chimerix acquisition), and Dr. Robert Iannone as EVP and Global Head of R&D. The company is backed by major institutional investors including The Vanguard Group, BlackRock, and Capital World Investors, with a board of directors featuring prominent figures such as Lead Independent Director Rick E. Winningham, CEO of Theravance Biopharma.